{4-[bis-(4-chlorophenyl)methyl]piperazin-1-yl}cyclobutylmethanone

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {4-[bis-(4-chlorophenyl)methyl]piperazin-1-yl}cyclobutylmethanone
• 英文别名: (4-(Bis(4-chlorophenyl)methyl)piperazin-1-yl)-(cyclobutyl)methanone；[4-[bis(4-chlorophenyl)methyl]piperazin-1-yl]-cyclobutylmethanone
• 化学式: C₂₂H₂₄Cl₂N₂O
• 分子量: 403.351
• InChiKey: HUANGXBYHXKJET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-(4,4'-二氯二苯甲基)哌嗪 、 环丁基甲酰氯 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 1,2-二氯乙烷 为溶剂， 以88%的产率得到{4-[bis-(4-chlorophenyl)methyl]piperazin-1-yl}cyclobutylmethanone
  参考文献：
  名称：

  WO2007/18459

  摘要：

  公开号：

文献信息

• Therapeutic Agents
  申请人：Empfield James R.

  公开号：US20080306087A1

  公开（公告）日：2008-12-11

  The present invention relates to compounds of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及式（I）的化合物及其制备过程，它们在肥胖、精神和神经疾病的治疗中的应用，以及它们的治疗用途和含有它们的制药组合物。
• Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands
  作者：Kwang-Seop Song、Sung-Han Lee、Hyun Ji Chun、Jong Yup Kim、Myung Eun Jung、Kwangwoo Ahn、Soo-Un Kim、Jeongmin Kim、Jinhwa Lee

  DOI：10.1016/j.bmc.2008.01.023

  日期：2008.4.1

  After the CB1 receptor antagonist SR141716 (rimonabant) was previously reported to modulate food intake, CB1 antagonism has been considered as a new therapeutic target for the treatment of obesity. Several series of urea, carbamate, amide, sulfonamide and oxalamide derivatives based on 1-benzhydrylpiperazine scaffold were synthesized and tested for CB1 receptor binding affinity. The SAR studies to optimize the CB1 binding affinity led to the potent urea derivatives. After the additional SAR studies to optimize the substituents of diphenyl rings, the combination of 2-chlorophenyl and 4-chlorophenyl turned out to be the most potent scaffold. The CB2 binding affinity assay as well as functional assay was also conducted on these compounds. Herein we wish to introduce several novel CB1 antagonists with IC50 values less than 100 nM for the CB1 receptor binding. (C) 2008 Elsevier Ltd. All rights reserved.
• THERAPEUTIC AGENTS
  申请人：AstraZeneca AB

  公开号：EP1915355A1

  公开（公告）日：2008-04-30
• [EN] THERAPEUTIC AGENTS<br/>[FR] AGENTS THÉRAPEUTIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2007018459A1

  公开（公告）日：2007-02-15

  [EN] The present invention relates to compounds of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.
  [FR] La présente invention concerne des composés de formule (I) et des procédés pour préparer de tels composés ; leur utilisation dans le traitement de l'obésité, de troubles psychiatriques et neurologiques ; des procédés pour leur utilisation thérapeutique ; et des compositions pharmaceutiques les contenant.
• WO2007/18459
  申请人：——

  公开号：——

  公开（公告）日：——